Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded…
The algorithms for treating psoriatic arthritis ( PsA ) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…
Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness; it encompasses multiple forms of chronic arthritis in children…
The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving non-TNF-α inhibitor agents to…
PsA, a disease hallmarked by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF-α…
Five TNF-α inhibitors and four biologics with alternative mechanisms of action are currently approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy, Spain,…
The U.S. rheumatoid arthritis (RA) market is crowded, with the availability of nine different biologics and Xeljanz, representing six distinct drug classes. With the impending entry of biosimilars…
The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting…
The prevalence of spondyloarthritis is increasing in China, where the estimated number of total prevalent cases of ankylosing spondylitis (AS) exceeds 1.6 million. Although the total prevalence of…
Introduction Rheumatoid arthritis (RA) affects a significant percentage of Argentinian and Mexican populations and often requires the use of premium-priced biologics. Rheumatologists have several…
:The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars and the…
Introduction: The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars…
Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists’ long-standing familiarity with the safety and efficacy…
Introduction Rheumatoid arthritis (RA) is a chronic disease that affects more than 1 million Brazilians and often requires the use of premium-priced therapies. The coverage of these drugs is…
Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic and, in many cases, debilitating diseases requiring lifelong treatment. Costs associated with biologic treatment for RA…
